873924-07-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid, 9-oxo-, 1,1-diMethylethyl ester is used as a building block or intermediate in the synthesis of pharmaceutical compounds for its unique structural features and potential biological activity.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid, 9-oxo-, 1,1-diMethylethyl ester serves as a key component in the creation of complex organic molecules, leveraging its reactive functional groups for further chemical transformations.
Used in Chemical Research:
3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid, 9-oxo-, 1,1-diMethylethyl ester is utilized in chemical research to explore its reactivity, stability, and potential interactions with other molecules, contributing to the understanding of spiro compounds and their applications in various chemical processes.

Upstream product

• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 6457-49-4 4-piperidinemethanol 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 2971-79-1 isonipecotic acid methyl ester 
• 78-94-4 methyl vinyl ketone 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 

Downstream Products

• 873924-08-4 9-oxo-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester 
• 1225437-12-6 9-(3,3-Difluoroazetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane 
• 1225437-01-3 tert-Butyl 9-(azetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225437-11-5 tert-Butyl 9-(3,3-difluoroazetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225437-13-7 tert-Butyl 9-(3-fluorophenyl)-9-(pyrrolidin-1-yl)-3-azaspiro[5.5]undecane-3-carboxylate 
• 1225436-55-4 1-(9-(azetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4-methoxy-2,6-dimethylphenylsulfonyl)piperidin-2-yl)methoxy)ethanone 
• 1225436-57-6 1-[3-(3-fluorophenyl)-3-pyrrolidin-1-yl-9-azaspiro[5.5]undecan-9-yl]-2-[1-[[3-(trifluoromethyl)phenyl]sulfonyl]-piperidin-2-yl]-ethanone 
• 1225436-56-5 1-(9-(3,3-difluoroazetidin-1-yl)-9-phenyl-3-azaspiro[5.5]undecan-3-yl)-2-(((S)-1-(4-methoxy-2,6-dimethylphenylsulfonyl)piperidin-2-yl)methoxy)ethanone 
• 1184103-34-1 3-(2'-pyridin-4-yl-8',9'-dihydro-6'h-spiro[piperidine-4,7'-pyrazolo[1,5-a]quinazolin]-3'-yl)phenol 
• 1184103-29-4 3'-(3-methoxyphenyl)-2'-pyridin-4-yl-8',9'-dihydro-6'h-spiro[piperidine-4,7'-pyrazolo[1,5-a]quinazoline] 
• 1184103-24-9 tert-butyl 3'-(3-methoxyphenyl)-2'-pyridin-4-yl-8',9'-dihydro-1H,6'H-spiro[piperidine-4,7'-pyrazolo[1,5-a]quinazoline]-1-carboxylate 
• 1184103-26-1 tert-butyl 3'-(3-methoxyphenyl)-2'-pyridin-4-yl-5',6'-dihydro-8'H-spiro[piperidine-4,7'-pyrazolo[5,1-b]quinazoline]-1-carboxylate 
• 1272758-41-4 9-amino-3-azaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR

Described herein are pharmaceutical compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-carboxamide, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto. Also described are compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-5 carboxamide, or pharmaceutically acceptable salt thereof and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto.

COMBINATIONS FOR TREATMENT OF NAFLD/NASH AND RELATED DISEASES

A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5- carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6- methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.

Combinations For Treatment Of NASH/NAFLD And Related Diseases

The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

CRYSTALLINE 2-AMINO-2-(HYDROXYMETHYL)PROPANE-1,3-DIOL SALT OF 4-(4-(1-ISOPROPYL-7-OXO-1,4,6,7-TETRAHYDROSPIRO[INDAZOLE-5,4'-PIPERIDINE]-1'-CARBONYL)-6-METHOXYPYRIDIN-2-YL)BENZOIC ACID

The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7- tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or tri-hydrate; as well as polymorphs, pharmaceutical compositions, dosage forms, and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase (ACC) enzyme(s) in an animal.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and composition thereof, and applicaitons of compounds and composition

The invention provides substituted heteroaryl compounds and a composition thereof, and applicaitons of the compounds and the composition. The compounds are compounds represented by the formula (I) or the formula (II) or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs of the compounds represented by the formula (I) or the formula (II). The invention also provides the pharmaceutical composition comprising the compounds; the compounds and the pharmaceutical composition can adjust the activity of protein kinase, and are used for prevention, processing, treatment and remission of diseases or disorders mediated by the protein kinase.

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted heteroaryl compound and a composition thereof, and applications of the compound and the composition. The compound is a compound as shown in a formula I, or stereoisomer, tautomer, oxynitride, solvate, metabolite, pharmaceutically-acceptable salt or prodrug of the compound as shown in the formula I. The invention also provides a pharmaceutical composition containing the above-mentioned compound; and the above-mentioned compound and the pharmaceutical composition are capable of adjusting the activity of JAK kinases and are applied in prevention, treatment, therapy and alleviation of JAK kinase mediated diseases or disorders.

Substituted heteroaryl compounds and compositions and uses thereof

The invention provides a substituted ceteroary compound as well as a composition and a purpose thereof. The substituted ceteroary compound is a compound shown as a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the pharmaceutically acceptable salt of the compound shown as the formula (I) and is used for regulating diseases or disorders mediated by one kind or various kinds of Janus kinase activities. The invention also provides a medicine composition containing the compound and a method of treating or alleviating the disease or disorder degree of a patient by inhibiting the Janus kinase activity.

Spiro aryl phosphorus oxide or sulfide

The invention discloses a spiro aryl phosphorus oxide or sulfide as ALK inhibitor, and in particular discloses a compound shown in a formula (I) as an ALK inhibitor or a pharmaceutically acceptable salt thereof.